WallStreetZenWallStreetZen

NASDAQ: KMPH
Kempharm Inc Stock

$5.51+0.23 (+4.36%)
Updated Jan 27, 2023
KMPH Price
$5.51
Fair Value Price
$7.31
Market Cap
$190.12M
52 Week Low
$4.00
52 Week High
$7.38
P/E
-1.94x
P/B
2.03x
P/S
20.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.72M
Earnings
-$35.23M
Gross Margin
98.2%
Operating Margin
-332.12%
Profit Margin
-328.6%
Debt to Equity
0.28
Operating Cash Flow
-$15M
Beta
1.4
Next Earnings
Mar 28, 2023
Ex-Dividend
N/A
Next Dividend
N/A

KMPH Overview

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KMPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KMPH ($5.51) is undervalued by 24.63% relative to our estimate of its Fair Value price of $7.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KMPH ($5.51) is significantly undervalued by 24.63% relative to our estimate of its Fair Value price of $7.31 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KMPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KMPH due diligence checks available for Premium users.

Be the first to know about important KMPH news, forecast changes, insider trades & much more!

KMPH News

Valuation

KMPH fair value

Fair Value of KMPH stock based on Discounted Cash Flow (DCF)
Price
$5.51
Fair Value
$7.31
Undervalued by
24.63%
KMPH ($5.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KMPH ($5.51) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KMPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KMPH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.94x
Industry
12.89x
Market
23.59x

KMPH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.03x
Industry
5.18x
KMPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KMPH's financial health

Profit margin

Revenue
$2.9M
Net Income
-$6.6M
Profit Margin
-230.2%
KMPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KMPH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$119.6M
Liabilities
$25.8M
Debt to equity
0.28
KMPH's short-term assets ($85.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KMPH's short-term assets ($85.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KMPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KMPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.6M
Investing
$272.0k
Financing
-$409.0k
KMPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KMPH vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KMPH$190.12M+4.36%-1.94x2.03x
OLMA$190.55M-0.63%-1.87x0.88x
CTXR$193.00M+0.76%-5.74x1.88x
PBYI$193.51M-4.07%19.27x8.73x
VRCA$193.55M-1.05%-4.57x4.32x

Kempharm Stock FAQ

What is Kempharm's quote symbol?

NASDAQ: KMPH) Kempharm trades on the NASDAQ under the ticker symbol KMPH. Kempharm stock quotes can also be displayed as NASDAQ: KMPH.

If you're new to stock investing, here's how to buy Kempharm stock.

What is the 52 week high and low for Kempharm (NASDAQ: KMPH)?

(NASDAQ: KMPH) Kempharm's 52-week high was $7.38, and its 52-week low was $4.00. It is currently -25.34% from its 52-week high and 37.75% from its 52-week low.

How much is Kempharm stock worth today?

(NASDAQ: KMPH) Kempharm currently has 34,504,862 outstanding shares. With Kempharm stock trading at $5.51 per share, the total value of Kempharm stock (market capitalization) is $190.12M.

Kempharm stock was originally listed at a price of $11.20 in Apr 16, 2015. If you had invested in Kempharm stock at $11.20, your return over the last 7 years would have been -50.8%, for an annualized return of -9.64% (not including any dividends or dividend reinvestments).

How much is Kempharm's stock price per share?

(NASDAQ: KMPH) Kempharm stock price per share is $5.51 today (as of Jan 27, 2023).

What is Kempharm's Market Cap?

(NASDAQ: KMPH) Kempharm's market cap is $190.12M, as of Jan 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kempharm's market cap is calculated by multiplying KMPH's current stock price of $5.51 by KMPH's total outstanding shares of 34,504,862.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.